PD‐L1 in gestational trophoblastic disease: an antibody evaluation

INTRODUCTION: Treatment with antibodies directed against programed‐cell death ligand 1 (PD‐L1) is a novel therapy for patients with gestational trophoblastic disease. Assessment of PD‐L1 expression in tumor tissue is commonly used to identify patients who might benefit from anti‐PD‐L1 treatment. Mul...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoeijmakers, Yvonne M., Simons, Michiel, Bulten, Johan, Gorris, Mark A. J., Ottevanger, Petronella B., de Vries, I. Jolanda M., Sweep, Fred C. G. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Pregnancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564454/
https://www.ncbi.nlm.nih.gov/pubmed/35689468
http://dx.doi.org/10.1111/aogs.14404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564454/
https://www.ncbi.nlm.nih.gov/pubmed/35689468
http://dx.doi.org/10.1111/aogs.14404

Ejemplares similares